Is KIORA PHARMACEUTICALS INC (KPRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.8% / 30% | 367.9% / 30% | 12.0% / 30% | 7.83% / 5% | ✗ NOT HALAL |
| DJIM | 0.8% / 33% | 367.9% / 33% | 12.0% / 33% | 7.83% / 5% | ✗ NOT HALAL |
| MSCI | 0.2% / 33% | 73.4% / 33% | 2.4% / 33% | 7.83% / 5% | ✗ NOT HALAL |
| S&P | 0.8% / 33% | 367.9% / 33% | 12.0% / 33% | 7.83% / 5% | ✗ NOT HALAL |
| FTSE | 0.2% / 33% | 73.4% / 33% | 2.4% / 50% | 7.83% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -51.7% | |
| Return on Assets (ROA) | -19.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $9M |
| Free Cash Flow | $9M |
| Total Debt | $57,170 |
| Debt-to-Equity | 2.3 |
| Current Ratio | 6.0 |
| Total Assets | $36M |
Price & Trading
| Last Close | $1.97 |
| 50-Day MA | $2.11 |
| 200-Day MA | $2.43 |
| Avg Volume | 47K |
| Beta | -0.8 |
|
52-Week Range
$1.76
| |
About KIORA PHARMACEUTICALS INC (KPRX)
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is KIORA PHARMACEUTICALS INC (KPRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), KIORA PHARMACEUTICALS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is KIORA PHARMACEUTICALS INC's debt ratio?
KIORA PHARMACEUTICALS INC's debt ratio is 0.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.2%.
What are KIORA PHARMACEUTICALS INC's key financial metrics?
KIORA PHARMACEUTICALS INC has a market capitalization of $7M, and revenue of $16M. Return on equity stands at -51.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.